PDUFA VI: Breakthrough Issues Among FDA Priorities
This article was originally published in The Pink Sheet Daily
Agency and industry also decide to drop research into using social media to enhance post-market safety monitoring.
You may also be interested in...
Breakthrough In Two Pages: FDA Offers Preliminary Advice
Agency now allows sponsors of potential breakthrough therapies to request preliminary advice, but sponsors may not necessarily want to use it.
Real-World Evidence: Efficacy Assessments Await FDA Clarity, Pilot Projects
Greater development and use of real-world evidence, such as pragmatic clinical trials and observational studies, to support regulatory decisions on drug efficacy are limited by regulatory, technical and practical hurdles, stakeholders say.
PDUFA Negotiations: Early Communications, Breakthrough Still On Docket
FDA and industry also talking about improvements to combination product review process as part of user fee program renewal.